LEO Pharma media fact sheet

Global leader in dermatology care

• LEO Pharma is a global pharmaceutical company dedicated to helping people achieve healthy skin.

• LEO Pharma has a dedicated workforce of around 4,800 employees in 61 countries. Approx. 1,600 employees are based in Denmark.

• LEO Pharma headquarters is in Denmark at Ballerup, outside Copenhagen.

• LEO Pharma’s products are sold in more than 100 countries. LEO Pharma develops, manufactures and markets products within dermatology and thrombosis.

• Within dermatology, LEO Pharma delivers treatment options for psoriasis, actinic keratosis, eczema and skin infections. LEO Pharma also delivers treatment options for thrombosis (blood clots).

• 125 million people worldwide suffer from psoriasis, according to the International Federation of Psoriasis Associations. 272 million people worldwide suffer from actinic keratosis, according to the World Health Organisation.

Focus on research and development

• Around 700 employees globally work in Research and Development at LEO Pharma. LEO Pharma also collaborates with more than 400 research centres and industry partners worldwide.

• Approx. 14% of LEO Pharma’s turnover is invested in R&D.

• During the last 10 years, LEO Pharma has initiated more than 100 clinical trials. Currently LEO Pharma is conducting clinical trials in four dermatological diseases and in the field of thrombosis. The trials span new chemical compounds with new mechanisms of action, improved delivery systems, product enhancements and global market expansion.

• LEO Pharma aims to be present in five skin conditions in five markets by 2015. LEO Pharma compliments internal R&D activities by actively exploring opportunities for in-licensing and acquisition internationally.

• LEO Pharma Research Foundation was established in 1947 and has since supported research within medicine, chemistry, biology and pharmacy. In 2008 it established two annual monetary awards for talented young researchers.
Strategy drives global growth

*In order to fulfil its vision of becoming the preferred dermatology care partner improving people’s lives around the world, LEO Pharma launched a global growth strategy in 2009. The strategy aims to increase competitiveness and help patients worldwide achieve better treatment outcomes through an innovative and focused approach.*

*In 2012, LEO Pharma noted a 10% increase in turnover in 2012 compared to the previous year (8,216 million DKK against 7,487 million DKK in 2011). LEO Pharma’s 2012 profit after tax 2012 amounted to 663 million DKK against 624 million DKK in 2011.*

*LEO Pharma’s holistic approach goes beyond products to offer complete care solutions. A leading example is QualityCare™, a patient support service that empowers people to take control of their skin condition.*

*LEO Pharma is expanding with new affiliates and own sales forces in new markets. In 2010, LEO Pharma established affiliates in USA, Brazil, Mexico, Hungary, Czech Republic and China and opened new production facilities in Denmark, France and Ireland. In 2011, LEO Pharma established affiliates in Australia and South Korea. In 2012, LEO Pharma established an affiliate in Italy. Affiliates in Russia, Hungary and South Korea are expected in 2013.*

*LEO Pharma launched a new product, Picato® (ingenol mebutate) gel, in the US in April 2012 as the first of many markets. Picato® gel is expected to be launched in 18 markets by the end of 2013. Picato® is gel is for treatment of actinic keratosi, a precursor to non-melanoma skin cancer.*

*LEO Pharma’s global workforce has increased by around 43% since the launch of the growth strategy in September 2009.*

**Group Management**

Gitte Aabo, President and CEO

Kim Kjøeller, Senior Vice President Global Development

Anders B. Spohr, Executive Vice President Global Product Supply

Lars Olsen, Executive Vice President Global Sales and Marketing

Annette S. Nielsen, Senior Vice President, Corporate Finance, IT and Legal Affairs
# Products

<table>
<thead>
<tr>
<th>Dermatology</th>
<th>Thrombosis</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daivobet® / Dovobet® / Taclonex®</td>
<td>Heparin LEO®</td>
<td>Burinex®</td>
</tr>
<tr>
<td>(calcipotriol betamethasone dipropionate)</td>
<td>(heparin sodium)</td>
<td>(bumetanide)</td>
</tr>
<tr>
<td>Daivonex® / Dovonex®</td>
<td>innohep®</td>
<td>Centyl®</td>
</tr>
<tr>
<td>(calcipotriol)</td>
<td>(tinzaparin sodium)</td>
<td>(bendroflumethiazide)</td>
</tr>
<tr>
<td>Fucidin®</td>
<td>One-Alpha® / EinsAlpha® / Etalpha®</td>
<td>Fucithalmic®</td>
</tr>
<tr>
<td>(fusidic acid / sodium fusidate)</td>
<td>(alfacalcidol)</td>
<td>(fusidic acid)</td>
</tr>
<tr>
<td>Fucidin® H</td>
<td>Protamine Sulphate LEO Pharma</td>
<td>Kaleorid®</td>
</tr>
<tr>
<td>(fusidic acid / hydrocortisone acetate)</td>
<td></td>
<td>(potassium chloride)</td>
</tr>
<tr>
<td>Fucicort® Lipid</td>
<td></td>
<td>Selexid®</td>
</tr>
<tr>
<td>(fusidic acid / betamethasone valerate)</td>
<td></td>
<td>(mecillinam/pivmecillinam)</td>
</tr>
<tr>
<td>Picato® (ingenol mebutate) gel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xamiol® / Taclonex Scalp® Topical Suspension</td>
<td></td>
<td>Divested in 2012</td>
</tr>
</tbody>
</table>
Owned by the LEO Foundation

- The LEO Foundation is an independent, private institution that assumed full ownership of LEO Pharma in 1986.
- The LEO Foundation has no external shareholders, which means all profit is reinvested into the company for the benefit of patients. This enables LEO Pharma to plan for long-term R&D.
- The foundation’s main aim is to ensure the long-term existence of the LEO Pharma group.

More than 100 years of history

- LEO Pharma was founded in Denmark in 1908 when two entrepreneurial pharmacists, Kongsted and Antons, bought a pharmacy in Copenhagen and set up pharmaceutical production in the basement using the latest technology.
- LEO Pharma was among the first to standardise drugs – giving patients access to safe, high-quality medicine at low cost. During World War II, LEO Pharma produced penicillin – making Denmark the third country in the world to produce the drug after the UK and US.

More information

Please visit www.leo-pharma.com for more information and press material for download.

*Updated April 16, 2013.*